SCHEMBL2822017

SCHEMBL2822017

Cc1nc(/C=C(\F)[C@H](O)CC(=O)N2C(=O)O[C@H](c3ccccc3)[C@@H]2C)co1

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 2/20 0.31
HDAC3 O15379 1/20 0.31
PTGDR2 Q9Y5Y4 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2822020 1.00 IDH1 (0.31) IDH1HDAC3PTGDR2
SCHEMBL2818413 1.00 IDH1 (0.31) IDH1HDAC3PTGDR2
SCHEMBL2818416 1.00 IDH1 (0.31) IDH1HDAC3PTGDR2
SCHEMBL2822032 0.85
SCHEMBL2822030 0.85
SCHEMBL5229660 0.85 IDH1 (0.31) IDH1PTGDR2
SCHEMBL5229789 0.84 IDH1 (0.34) IDH1PTGDR2
SCHEMBL5226729 0.84 IDH1 (0.34) IDH1PTGDR2
SCHEMBL5229785 0.84 IDH1 (0.34) IDH1PTGDR2
SCHEMBL5226727 0.84 IDH1 (0.34) IDH1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168179-A1 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS KLAR ULRICH 2010-07-01 US disclosed
US-7700621-B2 E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-20 US disclosed
US-7645891-B2 E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-01-12 US disclosed
EP-1173441-B1 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS BAYER SCHERING PHARMA AG (DE) 2009-08-26 EP disclosed
US-7125893-B1 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations SCHERING AG (DE) 2006-10-24 US disclosed
US-20060046997-A1 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations BAYER INTELLECTUAL PROPERTY GMBH (DE) 2006-03-02 US disclosed
US-20050113429-A1 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations BAYER INTELLECTUAL PROPERTY GMBH (DE) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046997-A1 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations TUBB6, CCNB1, TUBB IDH1 3268/4885HDAC3 3941/4885PTGDR2 170/4885
US-20100168179-A1 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS TUBB6, CCNB1, TUBB IDH1 3268/4885HDAC3 3941/4885PTGDR2 170/4885
US-20050113429-A1 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations TUBB6, CCNB1, TUBB IDH1 3245/4885HDAC3 3952/4885PTGDR2 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.